Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05838560
PHASE2

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Sponsor: Washington University School of Medicine

View on ClinicalTrials.gov

Summary

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

Key Details

Gender

All

Age Range

50 Years - Any

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2023-07-01

Completion Date

2026-08-01

Last Updated

2026-03-10

Healthy Volunteers

No

Interventions

DRUG

Dasatinib

dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.

DRUG

quercetin

The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States